Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Amedisys (AMED) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AMED or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMED vs. CHE: Which Stock Is the Better Value Option?
Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y
by Zacks Equity Research
Waters' (WAT) second-quarter results are hurt by weak end-market momentum and softness in Asia, Americas and Europe.
Philips (PHG) Q2 Earnings Rise, Revenues Fall Year Over Year
by Zacks Equity Research
Philips' (PHG) second-quarter results benefit from strong momentum across the Diagnosis & Treatment, Connected Care and Personal Health businesses.
AMED vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.
Compared to Estimates, Amedisys (AMED) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Amedisys (AMED) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amedisys (AMED) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 8.20% and 2.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Amedisys (AMED) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AMED or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Encompass Health (EHC), Piedmont Expand Ties to Serve Georgia
by Zacks Equity Research
Encompass Health (EHC) expands its partnership with Piedmont to better serve Georgians with the Walton Rehabilitation Hospital.
AMED vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Here's Why Amedisys (AMED) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AMED vs. USPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale
by Zacks Equity Research
By selling these assets, UnitedHealth (UNH) and Amedisys aim to avoid potential monopoly issues and ensure a smoother merger process.
Why Amedisys (AMED) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Amedisys (AMED) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Amedisys (AMED) Up 5.5% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Amedisys (AMED) tops on revenue and earnings estimates in the first quarter of fiscal 2024.
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Amedisys (AMED) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 1.98% and 1.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
by Zacks Equity Research
Humana (HUM) bumps up individual Medicare Advantage membership growth guidance.
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.